But I suspect this approach doesnt work as well in biopharma: Getting permission to be contrarian in biopharma is difficult : if the goal is to prove a contrarian opinion around a drug market, the company needs to not only develop a drug with great clinical data, but also carry out a commercial launch
Infliximab Infliximab (Remicade, Inflectra, Renflexis, infliximab-dyyb, and infliximab-abda) is a chimeric monoclonal antibody, used in the treatment of various autoimmune disorders like Crohn's disease, rheumatoid arthritis, ulcerative colitis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and Behet's disease
hnstedt E, Tomenius HL, Vgesj E, Phillipson M
GLP-1 lalar ve Bilimsel Gerekler Zayflama ilalar olarak bilinen GLP-1 reseptr agonistleri, son yllarda yalnzca kilo kayb ve diyabet tedavisiyle deil, kanser zerindeki olas etkileriyle de gndeme gelmektedir